Perez-Zsolt, Daniel
Muñoz-Basagoiti, Jordana
Rodon, Jordi http://orcid.org/0000-0002-1032-9091
Elosua-Bayes, Marc
Raïch-Regué, Dàlia http://orcid.org/0000-0001-7656-5700
Risco, Cristina http://orcid.org/0000-0001-7501-5934
Sachse, Martin
Pino, Maria
Gumber, Sanjeev
Paiardini, Mirko http://orcid.org/0000-0002-7276-3600
Chojnacki, Jakub
Erkizia, Itziar
Muñiz-Trabudua, Xabier
Ballana, Ester http://orcid.org/0000-0002-5215-7363
Riveira-Muñoz, Eva
Noguera-Julian, Marc
Paredes, Roger
Trinité, Benjamin
Tarrés-Freixas, Ferran
Blanco, Ignacio
Guallar, Victor
Carrillo, Jorge http://orcid.org/0000-0003-0221-5948
Blanco, Julià
Telenti, Amalio
Heyn, Holger http://orcid.org/0000-0002-3276-1889
Segalés, Joaquim http://orcid.org/0000-0002-1539-7261
Clotet, Bonaventura
Martinez-Picado, Javier http://orcid.org/0000-0002-4916-2129
Vergara-Alert, Júlia
Izquierdo-Useros, Nuria http://orcid.org/0000-0002-1039-1821
Article History
Received: 8 October 2021
Accepted: 10 October 2021
First Online: 15 November 2021
Change Date: 11 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41423-022-00893-y
Competing interests
: A patent application related to this work has been filed (US 63/152,346). Unrelated to the submitted work, J.C., J.B., and B.C. are founders and shareholders of AlbaJuna Therapeutics, S.L.; B.C. is a founder and shareholder of AELIX Therapeutics, S.L.; H.H. is cofounder and shareholder of OmniScope Limited; J.M.-P. reports institutional grants and educational/consultancy fees outside the submitted work from AbiVax, Astra-Zeneca, Gilead Sciences, Grifols, Janssen, Merck and ViiV Healthcare; and N.I.-U. reports institutional grants from Pharma Mar, Dentaid, Hipra, Grifols and Palobiofarma. The authors declare that no other competing financial interests exist.